Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

Benzer Materyaller

• Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
  Yazar:: Yamamoto, Noboru, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
  Yazar:: Yamamoto, Noboru, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study
  Yazar:: Yoshida, Kazushi, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
  Yazar:: Masuda, Chinami, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Bevacizumab for non‐small‐cell lung cancer: A nested case control study of risk factors for hemoptysis
  Yazar:: Goto, Koichi, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)